Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-11101 vs Darbepoetin Alfa in Hemodialysis Patients with Renal Anemia
NCT03428594Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of Nesbell in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Change in mean hemoglobin level and Mean administration dose. Started Jun 2015; status: completed.
02
Drugs
Nesbell
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03428594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428594.